RenalGuard Therapy

DEVICE4 trials

Sponsors

CardioRenal Systems, Inc., Sahlgrenska University Hospital, The Royal Wolverhampton Hospitals NHS Trust

Conditions

AKI - Acute Kidney InjuryAcute Kidney InjuryCardiac Surgery Associated - Acute Kidney InjuryCardiac Surgery SubjectsContrast Induced Nephropathy

Phase 3

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

CardioRenal Systems, Inc.Contrast Induced Nephropathy

Start: 2012-01-31End: 2024-12-31Updated: 2023-02-16

Unknown Phase

Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI

Active, not recruitingNCT06811805

CardioRenal Systems, Inc.AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury

Start: 2025-02-23End: 2028-04-30Target: 300Updated: 2026-01-23

PuO2 in RenalGuard Pilot Study

Not yet recruitingNCT06886191

Sahlgrenska University HospitalCardiac Surgery Subjects

Start: 2025-03-17End: 2026-12-31Target: 30Updated: 2025-03-20

Cost-effectiveness Analyses for the Prevention of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK

WithdrawnNCT07108634

The Royal Wolverhampton Hospitals NHS TrustAcute Kidney Injury

Start: 2026-03-01End: 2027-03-01Updated: 2026-03-16